Clinical Overview

Acne vulgaris is a chronic, multifactorial inflammatory disorder of the pilosebaceous unit characterized by comedonal, papular, pustular, and nodular lesions predominantly affecting adolescents and young adults. The condition represents the most prevalent skin disease in teenagers, with significant psychosocial consequences and potential for permanent scarring in severe cases.

Epidemiology

Acne vulgaris affects approximately 85% of individuals aged 12-24 years, with peak incidence during mid-teenage years (14-17 years). Adult-onset acne persists in 12-14% of individuals aged 25-44 years, with higher prevalence in women due to hormonal cycling. The condition generates substantial healthcare expenditure exceeding $1.2 billion annually in the United States when accounting for direct and indirect costs. Global prevalence estimates suggest 627-872 million individuals with clinically significant acne. Depression and anxiety occur in 27% of patients with moderate-to-severe acne, necessitating comprehensive psychosocial assessment.

Pathophysiology

Acne develops through four interconnected mechanisms: (1) sebaceous gland hyperplasia and increased sebum production driven by androgens, particularly dihydrotestosterone (DHT); (2) follicular epithelial hyperkeratinization causing comedone formation; (3) proliferation of Cutibacterium acnes (formerly Propionibacterium acnes); (4) innate and adaptive immune-mediated inflammation. DHT binds androgen receptors on sebaceous gland cells, increasing lipid synthesis through upregulation of sterol regulatory element-binding protein (SREBP). C. acnes lipopolysaccharide activates toll-like receptors 2 and 4, triggering IL-6, IL-8, and TNF-alpha release. Follicular hyperkeratinization creates anaerobic microenvironments favoring C. acnes proliferation. Inflammatory mediators subsequently activate NLRP3 inflammasome pathways, perpetuating pustule formation.

Clinical Presentation

Acne presents with distinctive lesion morphologies: non-inflammatory (open comedones with visible dark oxidized sebum, closed comedones appearing as skin-colored papules); inflammatory (papules 1-3mm erythematous, pustules with purulent centers); and nodular/cystic lesions (>5mm deep dermal/subcutaneous involvement, high scarring risk). Distribution typically involves the face (99% of cases), chest (15%), shoulders, and back (10%). Severity classification includes mild (primarily comedonal with occasional papules), moderate (mixed comedonal and inflammatory), moderate-severe (predominantly inflammatory with scattered nodules), and severe (confluent nodules, cystic lesions, possible systemic manifestations).

Diagnosis

Diagnosis is primarily clinical, based on characteristic lesion morphology and distribution. Histopathology reveals follicular keratosis, sebaceous gland hyperplasia, and perifollicular inflammation. Consider endocrinologic evaluation in female patients with sudden-onset severe acne, irregular menses, hirsutism, or post-adolescent acne (screening for PCOS or adrenal hyperplasia). Baseline serum lipid panel and liver function tests are mandatory before prescribing isotretinoin. Measurement of triglycerides, LDL, and AST/ALT should be obtained prior to treatment initiation.

Treatment Algorithm

Mild Acne: First-line includes topical retinoids (adapalene 0.1% nightly, tretinoin 0.025-0.1%, or retinyl palmitate) combined with benzoyl peroxide 2.5-10% daily. Azelaic acid 15-20% twice daily provides alternative for photosensitive patients. Duration: 8-12 weeks minimum to assess efficacy.

Moderate Acne: Combine topical retinoid with topical antibiotic (clindamycin 1% or erythromycin 2%) plus benzoyl peroxide, or prescribe oral antibiotics. First-line oral agents: doxycycline 100mg daily (superior to minocycline due to photostability) or minocycline 50-100mg daily. Limit antibiotic duration to 3-4 months to minimize resistance. Add oral contraceptives in females (particularly norgestimate-ethinyl estradiol, levonorgestrel-ethinyl estradiol, or drospirenone-containing formulations).

Moderate-Severe to Severe Acne: Isotretinoin (Accutane) is the gold standard with 90% achieving complete remission or long-term improvement. Dosing: 0.5-1.0 mg/kg/day initial, titrating to cumulative dose of 120-150 mg/kg over 4-6 months. iPLEDGE program enrollment mandatory (monthly pregnancy tests for females, contraception requirement, liver/lipid monitoring). Common side effects include cheilitis (80%), xerophthalmia (40%), myalgias (25%), and transient aminotransferase elevation (20%). Teratogenicity is absolute contraindication in pregnancy.

Acne in Females: Hormonal therapy options include combined oral contraceptives (norgestimate, drospirenone, cyproterone combinations) or spironolactone 100-200mg daily as antiandrogen (requires potassium/creatinine monitoring).

Prognosis

With appropriate treatment, 80% of patients achieve significant improvement within 12 weeks. Isotretinoin achieves sustained remission in 75-90% of patients; however, 15-20% experience relapse requiring retreatment. Untreated severe acne carries 40% risk of permanent atrophic or hypertrophic scarring. Post-inflammatory hyperpigmentation resolves within 6-12 months in most patients.

When to See a Dermatologist

Refer patients with: moderate acne unresponsive to topical therapy after 8-12 weeks; any nodular/cystic acne; rapid progression; severe psychological distress; acne resistant to antibiotics; or those requiring isotretinoin therapy. Dermatologists should assess scarring risk and recommend preventive strategies including resurfacing procedures (laser, chemical peels, microneedling) for established atrophic scars.

Frequently Asked Questions

Q: Can diet cause acne?
A: While dietary causation remains controversial, emerging evidence supports limiting high-glycemic-index foods and dairy products in susceptible individuals. Meta-analyses show modest associations between milk consumption and acne severity, particularly skim milk. Recommend trial elimination if dietary triggers suspected; however, primary therapy remains pharmacologic.

Q: How long until topical treatments work?
A: Minimum 8-12 weeks required for visible improvement with topical retinoids or antibiotics. Patients must be counseled regarding expected initial irritation from retinoids (erythema, peeling, dryness) during weeks 1-4. Combination therapies show faster response than monotherapy.

Q: Will acne leave permanent scars?
A: Severe untreated acne carries 40% scarring risk. Early aggressive treatment with isotretinoin prevents scar formation. Established atrophic scars respond to laser resurfacing (fractional CO2, 1540nm erbium), subcutaneous incision/excision, or combination therapies achieving 50-75% improvement.

Q: Is isotretinoin safe?
A: Isotretinoin carries significant teratogenic risk (25% rate of major congenital anomalies including cardiac, CNS, thymic, and cleft palate abnormalities). Strict contraception mandatory in females. Hepatotoxicity occurs in 15-20% (usually reversible). Elevated triglycerides develop in 40%, requiring monitoring. Rigorous benefit-to-risk analysis essential for severe, treatment-resistant acne.

References

  1. Zaenglein AL, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.
  2. Rocha RB, et al. Systemic treatment of acne. Semin Cutan Med Surg. 2018;37(2):100-106.
  3. Gollnick HP, et al. Management of acne. Dermatol Ther. 2012;2(6):1-11.
  4. Dosh SA. Acne management. Am Fam Physician. 2016;93(1):18-24.
  5. Melnik BC, et al. The role of mTORC1 in acne pathogenesis. Exp Dermatol. 2015;24(8):582-588.
  6. Ying S, et al. The role of immune cells in acne pathogenesis. Semin Immunopathol. 2021;43(1):105-118.
  7. Dreno B, et al. Epidemiology of acne. Dermatology. 2015;231(3):264-270.
  8. Williams HC, et al. Acne vulgaris. Lancet. 2012;379(9813):361-372.
  9. Zouboulis CC. Acne as an inflammatory disease. Int J Cosmet Sci. 2014;36(4):318-326.
  10. Suh DH, et al. Treatment-resistant acne: clinical approaches and therapeutic options. J Korean Med Sci. 2015;30(6):684-697.